Extracorporeal exposure of peripheral blood mononuclear cells to the photosensitizing agent 8-methoxypsoralen and UV-A radiation has been shown to be effective in the treatment of selected diseases mediated by T cells, rejection after solid organ transplantation, and chronic graft-versus-host disease (GVHD). We present 21 patients with a median age of 38 years who developed steroid-refractory acute GVHD grades II to IV after stem cell grafting from sibling or unrelated donors and were referred to extracorporeal photochemotherapy (ECP). Three months after initiation of ECP 60% of patients achieved a complete resolution of GVHD manifestations. Complete responses were obtained in 100% of patients with grade II, 67% of patients with grade III, and 12% of patients with grade IV acute GVHD. Three months after start of ECP complete responses were achieved in 60% of patients with cutaneous, 67% with liver, and none with gut involvement. Adverse events observed during ECP included a decrease in peripheral blood cell counts in the early phase after stem cell transplantation (SCT). Currently, 57% of patients are alive at a median observation time of 25 months after SCT. Probability of survival at 4 years after SCT is 91% in patients with complete response to ECP compared to 11% in patients not responding completely. Our findings suggest that ECP is an effective adjunct therapy for acute steroid-refractory GVHD with cutaneous and liver involvement. However, in patients with acute GVHD grade IV or gut involvement other therapeutic options are warranted.

Acute graft-versus-host disease (GVHD) is a major complication of allogeneic stem cell transplantation (SCT) that results in significant morbidity and mortality. Despite prophylaxis with cyclosporine (CSA) or methotrexate (MTX) or both, acute GVHD occurs in 30% to 50% of patients receiving transplants from HLA-identical sibling donors and in 50% to 80% of patients receiving transplants from HLA-matched unrelated donors.1-3 Acute GVHD is classified into 4 grades according to published criteria.4Long-term survival in patients developing severe acute GVHD has generally been less than 30%.5,6 Despite advances in the understanding of acute GVHD and its prophylaxis, little progress has been made in the primary treatment of established disease.7-9 Steroids constitute the main therapy, alone or in association with antithymocyte globulin (ATG), CSA, or monoclonal antibodies (mAb).8-10 Response and survival after acute GVHD depend on a number of variables, including patient clinical performance, infections, gastrointestinal bleeding, and pneumonitis, which often are associated with acute GVHD.8 9 Patients unresponsive to corticosteroids are at high risk of death due to infections.

Extracorporeal photochemotherapy (ECP) is currently being used for the treatment of cutaneous T-cell lymphoma, selected autoimmune diseases, and rejection after solid organ transplantation.11,12 ECP is based on the infusion of autologous peripheral blood mononuclear cells collected by apheresis, incubated with the photoactivable drug 8-methoxypsoralen (8-MOP) and UV-A irradiation. Recently, ECP has shown considerable efficacy in treatment of steroid-refractory chronic GVHD.13 14 

So far, results of ECP treatment have been reported in only a small number of patients with steroid-refractory acute GVHD including 6 previously treated patients at our institution.13-18 Here, we present results of a prospective pilot study with a larger number of patients with steroid-refractory acute GVHD grades II to IV treated with ECP.

Patients

The pretransplant characteristics of the patients are shown in Table 1. Data on the first 6 patients have previously been reported.13 Stem cell donors were HLA-identical siblings in 5 patients, HLA-identical unrelated donors in 12 patients, 1-antigen mismatched sibling donor in 1 patient, and 1-antigen mismatched unrelated donors in 3 patients. All patients had central venous catheters implanted on the day of admission. Catheters were removed between days 100 and 150 after SCT. Informed consent was obtained from all patients. Data were analyzed as of January 31, 2000.

Table 1.

Overall patient characteristics

No. of patients 21 
Median age (y) 38  
 Range 27-55 
Male/female 10/11  
Diagnosis  
 AML 
 ALL 5  
 CML 10  
 Others 3  
Conditioning regimen  
 CY/fTBI 19  
 BU/CY 2  
GVHD prophylaxis  
 CSA/MTX 20  
 CSA 1  
SC donors  
 Serologic and LBT match 17  
 Serologic class I mismatch 4  
 Related/unrelated 6/15  
SC source  
 BM 19  
 PBSC 
No. of patients 21 
Median age (y) 38  
 Range 27-55 
Male/female 10/11  
Diagnosis  
 AML 
 ALL 5  
 CML 10  
 Others 3  
Conditioning regimen  
 CY/fTBI 19  
 BU/CY 2  
GVHD prophylaxis  
 CSA/MTX 20  
 CSA 1  
SC donors  
 Serologic and LBT match 17  
 Serologic class I mismatch 4  
 Related/unrelated 6/15  
SC source  
 BM 19  
 PBSC 

AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia; CY, cyclophosphamide; fTBI, fractionated total body irradiation; BU, busulfan; GVHD, graft-versus-host disease; CSA, cyclosporine; MTX, methotrexate; SC, stem cell; LBT, ligation-based typing of class II; BM, bone marrow; PBSC, peripheral blood stem cells.

Evaluation criteria

From 1996 on, patients with clinicopathologic diagnosis of acute GVHD refractory to steroid treatment were treated with ECP. Due to the limited capacity for ECP at our institution, not all consecutive patients with severe steroid-refractory acute GVHD could receive ECP. Patients referred for ECP had baseline evaluations, including a history and physical examination, complete blood count with differential, and complete chemistry panel.

The clinical diagnosis of GVHD was confirmed by histopathology of the skin in all patients and, if indicated, liver or mucous membrane biopsies were clinically graded as 0 through IV for acute GVHD by the criteria reported4 and as none, limited, or extensive for chronic GVHD.19 Complete organ responses of acute GVHD were defined as resolution of skin, liver, or gut manifestations. Partial responses were defined as a more than 50% response in organ involvement, but less than a complete response. No change was defined as stable organ involvement, despite the tapering of other immunosuppressive agents by at least 50% of the dosage. No response referred to progressive worsening of acute GVHD and the inability to taper other medications. Steroid-refractory acute GVHD was defined as either no response of organ manifestations or inability to taper steroids without increased GVHD activity when steroids were given at a dose of at least 2 mg/kg body weight for at least 7 days.

ECP and treatment protocol

The ECP procedure was performed using the UVAR photopheresis system (Therakos, West Chester, PA), as described.13 The mean treatment time for the photopheresis procedure was 3.5 hours. Preferentially, peripheral vein catheters were used. ECP was initiated in patients with steroid-refractory acute GVHD when the white blood cell count was more than 1 × 109/L and no acute infections were observed. Patients were treated on 2 consecutive days (one cycle) at 1- to 2-week intervals until improvement and thereafter every 2 to 4 weeks until maximal response. Then, ECP was tapered on an individual basis. All adverse effects obtained during the treatments were recorded. Informed consent was obtained from the patients, and the use of ECP was approved by the medical ethics committee of the University of Vienna.

Skin biopsy

Punch biopsies (4 mm) were performed in all patients at onset of cutaneous GVHD, before ECP, and after improvement or resolution of GVHD on ECP. Skin biopsies were fixed in formalin, embedded in paraffin, and stained with hematoxylin-eosin. Sections were evaluated by light microscopy. The histopathologic diagnosis of acute cutaneous GVHD grades I to IV was based on the criteria and grading as suggested by Lerner and colleagues.20 

Statistical methods

Survival, incidence of transplant-related mortality, and relapse rates were estimated using the method of Kaplan and Meier. Comparisons were based on the generalized Wilcoxon test and the log-rank test.

All patients had restoration of normal hematopoiesis as indicated by rising blood cell counts and return of marrow cellularity within 4 weeks of stem cell grafting.

Acute GVHD and response to ECP

All patients experienced acute GVHD grades II to IV at a median of 19 days after SCT and did not respond to CSA and corticosteroids administered for a median of 21 days as shown in Table2. All patients had histologically proven cutaneous GVHD grades III to IV, 12 patients had liver involvement (including 2 patients with histologic confirmation) grades I to IV, and 4 patients had gut manifestations (including 3 patients with histologic confirmation) of GVHD grades II or III. One and 3 months after initiation of ECP 33% and 60% of patients, respectively, achieved a complete resolution of GVHD manifestations as shown in Figure1. The maximal response to ECP was achieved after a median of 4 cycles (range, 1-13 cycles) or 2 months (range, 0.5-6 months) of therapy.

Table 2.

Results of ECP in patients with acute steroid-refractory GVHD

Pt. no.Acute GVHDSteroids before ECPInterval SCT-ECP
(d)
Response to ECPTime off ECP (mo)Outcome
Grade Onset
(d)
Max dose (mg)Duration
(d)
SkinLiverGut
III 13 32 45 CR CR NA 16 Alive, CR 
III 12 20 36 CR CR NA 19 Alive, chron extens 
IV 13 10 15 34 PR NR NR NA Death (sepsis) 
II 13 29 42 CR CR NA NA Death (relapse) 
IV 13 10 29 42 PR NA NR NA Death (sepsis) 
IV 27 17 44 NC CR NA NA Death (sepsis) 
IV 15 10 22 37 CR CR NA NA Death (relapse) 
II 21 49 70 CR NA NA 41 Alive, CR 
II 14 23 37 CR NA NA 24 Alive, CR 
10 II 30 26 57 CR NA NA NA Death (relapse) 
11 II 26 44 CR NA NA 14 Alive, chron lim 
12 II 13 23 36 CR NA NA 15 Alive, CR 
13 II 18 21 48 CR NA NA 25 Alive, CR  
14 IV 25 10 34 PR CR NA Alive, chron extens 
15 III 18 24 42 CR CR NA 16 Alive, CR 
16 IV 14 23 38 PR NR NR NA Death (sepsis) 
17 II 33 42 CR CR NA Alive, CR 
18 II 19 14 42 CR NA NA Alive, CR 
19 IV 17 2.5 20 37 NC NC NA NA Death (H zost) 
20 IV 10 10 20 NC NR NR NA Death (MOF) 
21 II 32 42 NC NA NA NA* Alive, NC 
Pt. no.Acute GVHDSteroids before ECPInterval SCT-ECP
(d)
Response to ECPTime off ECP (mo)Outcome
Grade Onset
(d)
Max dose (mg)Duration
(d)
SkinLiverGut
III 13 32 45 CR CR NA 16 Alive, CR 
III 12 20 36 CR CR NA 19 Alive, chron extens 
IV 13 10 15 34 PR NR NR NA Death (sepsis) 
II 13 29 42 CR CR NA NA Death (relapse) 
IV 13 10 29 42 PR NA NR NA Death (sepsis) 
IV 27 17 44 NC CR NA NA Death (sepsis) 
IV 15 10 22 37 CR CR NA NA Death (relapse) 
II 21 49 70 CR NA NA 41 Alive, CR 
II 14 23 37 CR NA NA 24 Alive, CR 
10 II 30 26 57 CR NA NA NA Death (relapse) 
11 II 26 44 CR NA NA 14 Alive, chron lim 
12 II 13 23 36 CR NA NA 15 Alive, CR 
13 II 18 21 48 CR NA NA 25 Alive, CR  
14 IV 25 10 34 PR CR NA Alive, chron extens 
15 III 18 24 42 CR CR NA 16 Alive, CR 
16 IV 14 23 38 PR NR NR NA Death (sepsis) 
17 II 33 42 CR CR NA Alive, CR 
18 II 19 14 42 CR NA NA Alive, CR 
19 IV 17 2.5 20 37 NC NC NA NA Death (H zost) 
20 IV 10 10 20 NC NR NR NA Death (MOF) 
21 II 32 42 NC NA NA NA* Alive, NC 

Max indicates maximal; chron, chronic; lim, limited; extens, extensive; CR, complete response; PR, partial response; NC, no change; NR, no response; MOF, multiorgan failure; H zost, herpes zoster infection; NA, not applicable.

*

 Patient is currently under therapy.

Fig. 1.

Overall response of patients with acute steroid-refractory GVHD to ECP 1 month and 3 months after start of treatment.

Overall response of all patients (All) and, in addition, patients with acute GVHD grades II, III, and IV are presented. The left column shows response 1 month (mo) and the right column 3 months after start of ECP. Red and pale red, complete response; green and pale green, partial response; orange and pale orange, no change; yellow, no response; black, patients who were dead at 3 months.

Fig. 1.

Overall response of patients with acute steroid-refractory GVHD to ECP 1 month and 3 months after start of treatment.

Overall response of all patients (All) and, in addition, patients with acute GVHD grades II, III, and IV are presented. The left column shows response 1 month (mo) and the right column 3 months after start of ECP. Red and pale red, complete response; green and pale green, partial response; orange and pale orange, no change; yellow, no response; black, patients who were dead at 3 months.

Close modal

Response rates of different grades of acute GVHD are shown in Figure 1. Complete responses were achieved in 9 of 9 patients (100%) with grade II acute GVHD 3 months after start of ECP. Two of 3 patients (67%) with grade III and 1 of 8 patients (12%) with grade IV acute GVHD had a complete response. In the latter group 5 of 8 patients (64%) died within 3 months after initiation of ECP.

Response rates of patients with cutaneous manifestations of acute GVHD are shown in Figure 2. Three months after initiation of ECP complete responses were observed in 12 of 20 evaluable patients (60%) with cutaneous involvement including 11 of 13 patients (84%) with grade III and 1 of 7 patients (14%) with grade IV GVHD. In one patient the follow-up is currently less than 3 months. Another patient with cutaneous GVHD achieved a complete response 6 months after start of ECP. Five of 20 patients (25%) including 1 of 13 patients (8%) with grade III and 4 of 7 patients (58%) with grade IV GVHD died within 3 months of start of ECP.

Fig. 2.

Response of patients with acute steroid-refractory cutaneous GVHD to ECP.

Response of all patients (All) and, in addition, patients with acute GVHD grades III and IV is presented. The left column shows response 1 month (mo) and the right column 3 months after start of ECP. Red and pale red, complete response; green and pale green, partial response; orange and pale orange, no change; yellow, no response; black, patients who were dead at 3 months.

Fig. 2.

Response of patients with acute steroid-refractory cutaneous GVHD to ECP.

Response of all patients (All) and, in addition, patients with acute GVHD grades III and IV is presented. The left column shows response 1 month (mo) and the right column 3 months after start of ECP. Red and pale red, complete response; green and pale green, partial response; orange and pale orange, no change; yellow, no response; black, patients who were dead at 3 months.

Close modal

Patients with liver involvement due to acute GVHD and responding to ECP had a rapid normalization after a median of 3 weeks of therapy as shown in Figure 3. Eight of 12 patients (67%) with liver involvement experienced a complete resolution, documented in normalization of serum bilirubin and alkaline phosphatase levels after 3 months.

Fig. 3.

Response of patients with acute steroid-refractory GVHD and liver involvement to ECP.

Individual patients are listed (1-12) and different colors represent the various grades of acute GVHD according to Glucksberg. Arrows indicate ECP therapy.

Fig. 3.

Response of patients with acute steroid-refractory GVHD and liver involvement to ECP.

Individual patients are listed (1-12) and different colors represent the various grades of acute GVHD according to Glucksberg. Arrows indicate ECP therapy.

Close modal

Six of 9 patients (67%) with both skin and liver involvement achieved a complete response with ECP. No responses to ECP were observed in patients with combined skin, liver, and gut involvement as shown in Table 2.

During ECP, steroid therapy could be discontinued in responding patients after a median of 53 days (range, 18-122 days). After termination of ECP, patients remained on CSA for 2 months, but the dosage was subsequently reduced and finally treatment was terminated.

Infections and adverse events

Six patients died during the study period, 5 from infections related to deteriorating GVHD (patient nos. 3, 5, 6, 16, and 19) and 1 from multiorgan failure and severe gastrointestinal bleeding (patient no. 20) related to gut GVHD. Probability of transplant-related mortality (TRM) projected at 4 years after SCT was 32% for the entire group. In patients achieving a complete response of acute steroid-refractory GVHD, the TRM was 0% compared to 75% in patients without complete response 3 months after ECP, respectively. These differences are highly significant (P = .001).

Adverse events observed during a total of 230 cycles (460 procedures) of ECP are shown in Table 3.

Table 3.

Adverse events during study period

No. patientsNo. episodes (%)
Decrease in Hb ≥ 1 g/dL 19 74  (16)  
Renewed RBC transfusion requirement 10 26  (6)  
Drop of ANC to < 1.5 × 109/L 17 40  (9)  
Drop of ANC to < 1 × 109/L 12  (3)  
Drop of ANC to < 0.5 × 109/L 5  (1)  
Decrease of Plts ≥ 50% 15 75  (16)  
Drop of Plts to < 20 × 109/L 8  (2)  
Renewed Plts transfusion requirement 20  (4)  
Bacterial infections   
 Sepsis 9   
 Urinary tract 2   
 Sinusitis 1   
 Ileitis 1  
Fever of unknown origin 14 21   
Viral infections   
 CMV reactivation 11 12   
 Herpes simplex/zoster 14   
Fungal infections   
 Sepsis 2   
 Stomatitis 4  
Bleeding 3  
No. patientsNo. episodes (%)
Decrease in Hb ≥ 1 g/dL 19 74  (16)  
Renewed RBC transfusion requirement 10 26  (6)  
Drop of ANC to < 1.5 × 109/L 17 40  (9)  
Drop of ANC to < 1 × 109/L 12  (3)  
Drop of ANC to < 0.5 × 109/L 5  (1)  
Decrease of Plts ≥ 50% 15 75  (16)  
Drop of Plts to < 20 × 109/L 8  (2)  
Renewed Plts transfusion requirement 20  (4)  
Bacterial infections   
 Sepsis 9   
 Urinary tract 2   
 Sinusitis 1   
 Ileitis 1  
Fever of unknown origin 14 21   
Viral infections   
 CMV reactivation 11 12   
 Herpes simplex/zoster 14   
Fungal infections   
 Sepsis 2   
 Stomatitis 4  
Bleeding 3  

Hb indicates hemoglobin; RBC, red blood cells; ANC, absolute neutrophil counts; Plts, platelets; CMV, cytomegalovirus.

Survival and long-term outcome

Three patients (no. 2, 8, and 11) developed chronic GVHD 5 to 28 months after SCT and 1.5 to 17 months after discontinuation of ECP. Another patient (no. 14) progressed into chronic extensive GVHD and requires combined immunosuppressive therapy.

As of January 31, 2000, 12 of 21 patients (57%) are alive a median of 25 months (range, 2-53 months) after SCT. Five patients are off immunosuppression and 3 during CSA taper with a Karnofsky performance score above 90%.

Probability of survival at 4 years after SCT is 53% for the entire group as shown in Figure 5. In patients achieving a complete response of acute steroid-refractory GVHD 6 months after initiation of ECP, probability of survival was 91% compared to 11% in patients without complete response of GVHD to ECP. These differences are statistically significant (P = .0001).

Fig. 4.

Kaplan-Meier probability of overall survival of patients with acute steroid-refractory GVHD.

Overall survival is shown for all patients (All) and patients achieving a complete response (CR) or no CR to ECP. The difference between the 2 groups is significant at P = .0001.

Fig. 4.

Kaplan-Meier probability of overall survival of patients with acute steroid-refractory GVHD.

Overall survival is shown for all patients (All) and patients achieving a complete response (CR) or no CR to ECP. The difference between the 2 groups is significant at P = .0001.

Close modal

At present, corticosteroids are the first-line therapy for severe acute GVHD, achieving response rates of 24% to 70%.5,8-10 In a recent study the increase of steroid dose to 10 to 20 mg/kg body weight did not improve overall response and survival of GVHD patients.21 Various second-line immunosuppressive options for these patients have been investigated.10,22-27 Using ATG in steroid-refractory acute GVHD, overall response rates of 30% to 40% have been observed.10,22,27 Recently, Przepiorka and coworkers28 observed complete response rates of 29% to 47% using daclizumab, a humanized anti-interleukin-2 receptor (IL-2R) α-chain antibody. With anti-CD2 mAbs complete response rates of 30% have been achieved in patients with steroid-refractory acute GVHD.23 29 

In search of further therapeutic options for patients with steroid-refractory acute GVHD and based on our results achieved with ECP in selected patients with severe resistant chronic GVHD,13 ECP was investigated as a second-line treatment in 21 patients with acute GVHD not responding to steroids at a dose of at least 2 mg/kg body weight. Three months after initiation of ECP 60% of patients achieved a complete resolution of GVHD manifestations. The maximal response to ECP was achieved after a median of 2 months. High complete response rates were achieved in patients with cutaneous (65%) and liver (67%) involvement and grades II (100%) to III (67%) of acute steroid-refractory GVHD. These results compare favorably with the ones achieved with mAbs against IL-2R or CD2.28,29 So far, only a few patients with acute GVHD treated with ECP have been reported.13-18 Whereas Sniecinski and colleagues15 and Besnier and coworkers16observed no response in a total of 7 patients, a complete resolution of grade III GVHD was achieved by Richter and associates17 in 1 patient. Dall'Amico and Zacchello18 documented improvements of acute GVHD in 3 of 4 pediatric patients during ECP.

Due to the rapid response to ECP, the dose of steroids could be reduced and discontinued after a median of 53 days in our responding patients. In view of the severe side effects of prolonged high-dose corticosteroid therapy the timely discontinuation of steroids is a major advantage for these patients.

The overall survival rate of 57% after a median observation time of 25 months after SCT in our study compares favorably with published results on second-line therapy of patients with acute steroid-refractory GVHD.25-29 A significantly higher probability of survival (91%) was seen in patients achieving a complete response 6 months after initiation of ECP compared to patients not responding (11%). Recently, failure of first-line therapy of acute GVHD has been reported as a significant factor in a multivariate analysis for poor 2-year survival with 10% survival rate in nonresponders and 54% in responders.30 The deaths observed in our study consisted of GVHD-associated infections and multiorgan failure and are similar to the ones reported in patients not responding to alternative GVHD therapies.

Extracorporeal photochemotherapy usually is tolerated excellently with very few side effects.14 In contrast to patients treated with ECP at our institution for chronic extensive GVHD, patients in the early phase after SCT had a marked decrease in hemoglobin levels, absolute neutrophil counts, and platelet counts after the first cycles of ECP. No increase in rate of infections during and after ECP compared with previously published results in these patients was seen in our study.5,8,9 21 

The optimal duration and schedule of ECP treatment are still unclear. Our treatment schedule is based on clinical experience gained in patients with selected autoimmune diseases and chronic GVHD.11-13 Due to concerns about reactivation of GVHD activity after initial response, no abrupt discontinuation of ECP was performed and individual tapering of therapy occurred in our study. The results obtained support the use of ECP over a short treatment time because patients responding did so almost exclusively in the first 3 months, whereas little additional benefit could be obtained by continuation of ECP for a longer time. Whereas patients treated with mAbs had a hyporesponsive state of limited duration with high recurrence rates of GVHD after completion of therapy,23 29the majority of our patients had sustained resolution of GVHD activity.

The exact mechanisms by which ECP leads to the described responses in GVHD as well as other T-cell–mediated diseases have not been elucidated. ECP may be involved in augmenting the apoptotic process,31,32 which may lead to deletion of graft-reactive T cells. Another possibility is that the photoactivated 8-MOP may alter the idiotypes expressed by clones of autoreactive T cells of known or unknown specificity by up-regulation of class I expression.33 This might trigger the induction of specific autoregulatory T cells, most likely CD8+ T lymphocytes with suppressive or cytotoxic capabilities.34 Findings in the animal model support this concept.35 36 These hypotheses, however, warrant further investigation because most of the in vitro studies involving ECP, so far, have been performed in patients with neoplastic or autoimmune diseases.

In summary, our results demonstrate that ECP is an efficacious and well tolerated therapy for patients with acute steroid-refractory GVHD. Timely identification of nonresponding or incomplete responding patients allows early assignment to alternate immunosuppressive treatment. The early combination of ECP with other treatment strategies including mAbs could further improve survival of patients with gastrointestinal involvement or grade IV acute GVHD. However, randomized studies are mandatory to evaluate the impact of ECP on outcome of patients with GVHD.

We thank the dedicated nurses of our stem cell transplant program and the ECP unit, our fellows and house staff, the medical technicians, and the physicians who referred patients to our unit. We are indebted to the members of Geben fuer Leben–Knochenmarkspende Oesterreich for finding suitable unrelated donors for our patients.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

1
Storb
R
Deeg
HJ
Whitehead
J
et al
Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia.
N Engl J Med.
314
1986
729
735
2
Beatty
PG
Hansen
JA
Longton
GM
et al
Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies.
Transplantation.
51
1991
443
447
3
Ringden
O
Backman
L
Lonnqvist
B
et al
A randomized trial comparing use of cyclosporin and methotrexate for graft-versus-host disease prophylaxis in bone marrow transplant recipients with haematological malignancies.
Bone Marrow Transplant.
1
1986
41
51
4
Rowlings
PA
Przepiorka
D
Klein
JP
et al
IBMTR severity index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade.
Br J Haematol.
97
1997
855
864
5
Weisdorf
D
Haake
R
Blazar
B
et al
Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome.
Blood.
75
1990
1024
1030
6
Nash
RA
Pepe
MS
Storb
R
et al
Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate.
Blood.
80
1992
1838
1845
7
Ferrara
JL
The cytokine modulation of acute graft-versus-host disease.
Bone Marrow Transplant.
21(suppl 3)
1998
13
8
Hings
IM
Severson
R
Filipovich
AH
et al
Treatment of moderate and severe acute GVHD after allogeneic bone marrow transplantation.
Transplantation.
58
1994
437
442
9
Deeg
HJ
Hensley-Downey
PJ
Management of acute graft-versus-host disease.
Bone Marrow Transplant.
6
1990
1
8
10
Doney
KC
Weiden
PL
Storb
R
et al
Treatment of graft-versus-host disease in human allogeneic marrow graft recipients: a randomized trial comparing antithymocyte globulin and corticosteroids.
Am J Hematol.
11
1981
1
8
11
Edelson
RL
Heald
PW
Perez
MI
et al
Extracorporeal photochemotherapy.
Biol Ther Cancer Updates.
4
1994
2
12
12
Barr
ML
Meiser
BM
Eisen
HJ
et al
Photopheresis for the prevention of rejection in cardiac transplantation.
N Engl J Med.
339
1998
1744
1751
13
Greinix
HT
Volc-Platzer
B
Rabitsch
W
et al
Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease.
Blood.
92
1998
3098
3104
14
Greinix HT, Volc-Platzer B, Knobler RM. Extracorporeal photochemotherapy in the treatment of severe graft-versus-host disease. Leuk Lymph. In press.
15
Sniecinski
I
Extracorporeal photochemotherapy: a scientific overview.
Transfus Sci.
15
1994
429
442
16
Besnier
DP
Chabannes
D
Mahe
B
et al
Treatment of graft-versus-host disease by extracorporeal photochemotherapy.
Transplantation.
64
1997
49
54
17
Richter
HI
Stege
H
Ruzicka
T
et al
Extracorporeal photopheresis in the treatment of acute graft-versus-host disease.
J Am Acad Dermatol.
36
1997
787
789
18
Dall'Amico
R
Zacchello
G
Treatment of graft-versus-host disease with photopheresis.
Transplantation.
65
1998
1283
1284
19
Sullivan
KM
Shulman
HM
Storb
R
et al
Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression.
Blood.
57
1981
267
276
20
Lerner
KG
Kao
GF
Storb
R
Histopathology of graft-versus-host reaction (GVHR) in human recipients from HLA-matched sibling donors.
Transplant Proc.
6
1974
367
371
21
Van Lint
MT
Uderzo
C
Locasciulli
A
et al
Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation.
Blood.
92
1998
2288
2293
22
Deeg
HJ
Loughran
TP
Storb
R
et al
Treatment of human acute graft-versus-host disease with antithymocyte globuline and cyclosporine with or without methylprednisolone.
Transplantation.
40
1985
162
166
23
Herve
P
Tiberghien
P
Racadot
E
et al
Prevention and treatment of acute GvHD-new modalities.
Bone Marrow Transplant.
11(suppl 1)
1993
103
106
24
Anasetti
C
Hansen
JA
Waldmann
TA
et al
Treatment of acute graft-versus-host disease with humanized anti Tac: an antibody that binds to the interleukin-2 receptor.
Blood.
84
1994
1320
1327
25
Hebart
H
Ehninger
G
Schmidt
H
et al
Treatment of steroid resistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies.
Bone Marrow Transplant.
15
1995
891
894
26
Lazarus
HM
Rowe
JM
New and experimental therapies for treating graft-versus-host disease.
Blood Rev.
9
1995
117
133
27
Martin
PJ
Schoch
G
Fisher
L
et al
A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment.
Blood.
77
1991
1821
1828
28
Przepiorka
D
Kernan
NA
Ippoliti
C
et al
Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease.
Blood.
95
2000
83
89
29
Przepiorka
D
Phillips
GL
Ratanatharathorn
V
et al
A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease.
Blood.
92
1998
4066
4071
30
Pavletic
S
Tarantolo
S
Lynch
J
et al
Acute graft-versus-host disease after allogeneic blood stem cell transplantation: factors determining treatment failure and survival.
Blood.
94(suppl 1)
1999
153a
31
Aringer
M
Graninger
WB
Smolen
JS
et al
Photopheresis treatment enhances CD95 (FAS) expression in circulating lymphocytes of patients with systemic sclerosis and induces apoptosis.
Br J Rheumatol.
36
1997
1276
1282
32
Yoo
EK
Rook
AH
Elenitsas
R
et al
Apoptosis induction by ultraviolet light A and photochemotherapy in cutaneous T-cell lymphoma: relevance to mechanism of therapeutic action.
J Invest Dermatol.
107
1996
235
242
33
Lambert
M
Ronai
Z
Weinstein
IB
et al
Enhancement of major histocompatibility class I protein synthesis by DNA damage in cultured human fibroblasts and keratinocytes.
Mol Cell Biol.
9
1989
847
850
34
Ware
R
Jiang
H
Braunstein
N
et al
Human CD8+ T lymphocyte clones specific for T cell receptor V beta families expressed on autologous CD4+ T cells.
Immunity.
2
1995
177
184
35
Girardi
M
Herreid
P
Tigelaar
RE
Specific suppression of lupus-like graft-versus-host disease using extracorporeal photochemical attenuation of effector lymphocytes.
J Invest Dermatol.
104
1995
177
182
36
Berger
CL
Perez
M
Laroche
L
Edelson
R
Inhibition of autoimmune disease in a murine model of systemic lupus erythematosus induced by exposure to syngeneic photoinactivated lymphocytes.
J Invest Dermatol.
94
1990
52
57

Author notes

Hildegard T. Greinix, AKH Wien, Klinik fuer Innere I, Knochenmarktransplantation, Waehringer Guertel 18-20, A-1090, Vienna, Austria; e-mail:hildegard.greinix@akh-wien.ac.at.

Sign in via your Institution